<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="other nine medicines, brincidofovir, an ether lipid ester analog of" exact="cidofovir" post="with potent antiviral activity, showed the highest docking scores"/>
 <result pre="(PDB codeâ€‰=â€‰1Q2W) Drug name Ligand Receptor Interaction Distance E (kcal/mol)" exact="Atovaquone" post="6-ring CD PRO 122 (B) pi-H 4.11 âˆ’Â 0.5"/>
 <result pre="Atovaquone 6-ring CD PRO 122 (B) pi-H 4.11 âˆ’Â 0.5" exact="Chloroquine" post="O 5 NZ LYS 5 (A) H-acceptor 3.34 âˆ’Â"/>
 <result pre="0.6 6-ring CA GLY 2 (B) pi-H 3.49 âˆ’Â 0.5" exact="Doxycycline" post="N 6 N GLN 127 (A) H-acceptor 3.27 âˆ’Â"/>
 <result pre="N 9 N GLN 127 (B) H-acceptor 3.32 âˆ’Â 2.3" exact="Ribavirin" post="O 1 O PHE 3 (B) H-donor 2.98 âˆ’Â"/>
 <result pre="receptor (PDB codeâ€‰=â€‰6M0J) Drug Ligand Receptor Interaction Distance E (kcal/mol)" exact="Atovaquone" post="6-ring CA VAL 209 (A) pi-H 3.90 âˆ’ 1.0"/>
 <result pre="Atovaquone 6-ring CA VAL 209 (A) pi-H 3.90 âˆ’ 1.0" exact="Chloroquine" post="N 17 O GLU 208 (A) H-donor 3.16 âˆ’"/>
 <result pre="0.6 6-ring N ASN 210 (A) pi-H 3.62 âˆ’ 0.6" exact="Doxycycline" post="O 24 OE1 GLU 208 (A) H-donor 3.01 âˆ’"/>
 <result pre="O 12 NZ LYS 94 (A) H-acceptor 3.12 âˆ’ 3.5" exact="Ribavirin" post="O 15 NZ LYS 562 (A) H-acceptor 3.03 âˆ’"/>
 <result pre="3.01 âˆ’ 1.2 Table 5 Docking score and energy of" exact="ivermectin" post="drug and 1Q2W of COVID-19 with site 1 of"/>
 <result pre="protease (PDB codeâ€‰=â€‰1Q2W) Table 6 Docking score and energy of" exact="ivermectin" post="drug with ACE-2 receptor (PDB codeâ€‰=â€‰6M0J) Fig.Â 1 3d"/>
 <result pre="with ACE-2 RECEPTOR (PDB CODEâ€‰=â€‰6M0J) Fig.Â 5 Chemical structure of" exact="ivermectin" post="Brincidofovir (BCV) is an orally bioavailable, long-acting nucleotide analog"/>
 <result pre="with an enhanced cellular penetration prodrug of cidofovir, wherein the" exact="cidofovir" post="acyclic nucleoside monophosphate is conjugated through its phosphonate group"/>
 <result pre="particle, the compound ensures better and higher intracellular releases of" exact="cidofovir" post="and lower plasma concentrations of the active drug, effectively"/>
 <result pre="effectively increasing its antiviral activity. When intracellular, the released free" exact="cidofovir" post="from the BCV is phosphorylated to its active metabolite"/>
 <result pre="cidofovir from the BCV is phosphorylated to its active metabolite" exact="cidofovir" post="diphosphate, which, due to its structural similarity to the"/>
 <result pre="investigations using molecular docking to check the binding interaction between" exact="ivermectin" post="and the SARS-CoV-2 protease and receptor. We got comparable"/>
 <result pre="better recommended because for its high lipophilicity â€œ5.54â€�, whereas for" exact="ivermectin" post="it is â€œ2.01â€�. In conclusion, molecular modeling tools were"/>
 <result pre="SARS coronavirus main proteaseWorldw Protein Data Bank200310.2210/pdb1q2w/pdb CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir Res202017810478710.1016/j.antiviral.2020.10478732251768 ChiangC-MFaculty"/>
 <result pre="dsDNA virusesExpert Rev Anti-infect Ther2014121171117810.1586/14787210.2014.94884725120093 FramptonJETafenoquine: first global approvalDrugs2018781517152310.1007/s40265-018-0979-230229442 GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="of therapeutic intervention with an oral ether lipid analogue of" exact="cidofovir" post="(CMX001) in a lethal mousepox modelAntivir Res200878A61A6210.1016/j.antiviral.2008.01.132 ParkerSet al.Efficacy"/>
 <result pre="al.Efficacy of therapeutic intervention with an oral etherâ€&quot;lipid analogue of" exact="cidofovir" post="(CMX001) in a lethal mousepox modelAntiviral Res200877394910.1016/j.antiviral.2007.08.00317904231 Schepers J."/>
</results>
